Prater M R, Taylor H, Munshi R, Linden J
Department of Internal Medicine (Cardiology), University of Virginia Health Center, Charlottesville 22908.
Mol Pharmacol. 1992 Nov;42(5):765-72.
Guanine nucleotides such as guanosine 5'-(3-O-thio)triphosphate (GTP gamma S) have been found to increase the binding of antagonists to adenosine A1 receptors. This response can be attributed either to a direct effect of GTP on receptors to increase antagonist affinity or to an indirect effect to decrease the affinity of receptors for a pool of endogenous adenosine that cannot be readily removed from membranes. In this study, adenosine content was measured in preparations of membranes and 3-[(3-cholamidopropyl)dimethylamino]-1-propanesulfonate (CHAPS)-solubilized receptors by a sensitive radioimmunoassay. In both preparations, pools of adenosine (2.5-10 pmol/mg of protein) were detected that were resistant to deamination by added adenosine deaminase (0.5-3 units/ml) unless membrane lipids were first dissolved in acetone. Electron microscopic examination of crude CHAPS-solubilized receptors revealed the existence of small vesicles (< 1 microns in diameter). Furthermore, most "solubilized" receptors were retained by a 0.1-microns filter. The effects of GTP gamma S were evaluated on the binding of an antagonist, 3-(4-amino-3-125I-phenethyl)-1-propyl-8-cyclopentylxanthine (125I-BW-A844U), to A1 receptors of bovine brain membranes, receptors solubilized in CHAPS (crude solubilized), or receptors partially co-purified with G proteins by agonist affinity chromatography (partially purified). GTP gamma S (10 microM) increased antagonist binding to membranes (20-50%) and crude CHAPS-solubilized receptors (> 200%) but increased binding to partially purified receptors by only 10-15%. GTP gamma S decreased agonist (125I-N6-aminobenzyladenosine) binding and increased antagonist Bmax, but did not significantly decrease (5%) the dissociation rate of the antagonist. Omission of Mg2+ mimicked the effects of GTP gamma S on agonist and antagonist binding and increased both the association and dissociation rates of 125I-BW-A844U. These data suggest that a Mg(2+)-dependent GTP gamma S-induced increase in antagonist binding to membranes and solubilized receptors is primarily due to unmasking of cryptic binding sites occupied by contaminating vesicular adenosine. These findings are consistent with the observation that adenosine receptor antagonists have been found to have little or no inverse agonist physiological effects in well oxygenated tissues.
已发现鸟嘌呤核苷酸,如鸟苷5'-(3-O-硫代)三磷酸(GTPγS),可增加拮抗剂与腺苷A1受体的结合。这种反应可能归因于GTP对受体的直接作用,以增加拮抗剂亲和力,或者归因于间接作用,即降低受体对内源性腺苷池的亲和力,而内源性腺苷池不易从膜中去除。在本研究中,通过灵敏的放射免疫测定法测量了膜制剂和3-[(3-胆酰胺丙基)二甲基氨基]-1-丙烷磺酸盐(CHAPS)溶解的受体中的腺苷含量。在这两种制剂中,均检测到腺苷池(2.5-10 pmol/mg蛋白质),除非膜脂质首先溶解在丙酮中,否则该腺苷池对添加的腺苷脱氨酶(0.5-3单位/ml)的脱氨作用具有抗性。对粗制CHAPS溶解的受体进行电子显微镜检查,发现存在小囊泡(直径<1微米)。此外,大多数“溶解”的受体被0.1微米的滤器截留。评估了GTPγS对拮抗剂3-(4-氨基-3-125I-苯乙基)-1-丙基-8-环戊基黄嘌呤(125I-BW-A844U)与牛脑膜A1受体、CHAPS中溶解的受体(粗制溶解物)或通过激动剂亲和色谱法与G蛋白部分共纯化的受体(部分纯化)结合的影响。GTPγS(10μM)增加了拮抗剂与膜(20-50%)和粗制CHAPS溶解的受体(>200%)的结合,但仅使与部分纯化受体的结合增加了10-15%。GTPγS降低了激动剂(125I-N6-氨苄基腺苷)的结合并增加了拮抗剂的Bmax,但并未显著降低(5%)拮抗剂的解离速率。省略Mg2+模拟了GTPγS对激动剂和拮抗剂结合的影响,并增加了125I-BW-A844U的结合和解离速率。这些数据表明,Mg(2+)依赖性的GTPγS诱导的拮抗剂与膜和溶解受体结合的增加主要是由于被污染的囊泡腺苷占据的隐蔽结合位点被暴露。这些发现与以下观察结果一致,即在充分氧合的组织中,腺苷受体拮抗剂几乎没有或没有反向激动剂的生理作用。